Ferrari Option Alert: Dec 19 $350 Calls at the Bid: 30 vs 63 OI

Ferrari Option Alert: Dec 19 $350 Calls at the Bid: 30 @ $170.0 vs 63 OI; Ref=$503.01

Ferrari (NYSE:RACE) 주식

Ferrari

Ferrari designs, engineers, and manufactures some of the world's most expensive luxury cars. With supply carefully controlled to be below demand and a brand steeped in decades of motor racing history, a Ferrari is viewed as a status symbol. In 2023, the company sold 13,663 vehicles at an average price over EUR 400,000 with more than 70% of its vehicles being sold to existing Ferrari clients. Eighty-six percent of revenue is generated from the sale of cars and spare parts and 10% from sponsorship, commercial, and brand activities including racing and lifestyle activities. In 2023, the Europe, Middle East, and Africa region accounted for 48% of revenue, the Americas was 30%, mainland China, Hong Kong, and Taiwan was 10%, and the rest of Asia was 13%.

News

RACE

STLA

자동차 제조업체들은 도널드 트럼프 대통령의 세금 인상 제안으로 인해 글로벌 생산 전략이 흔들릴 위험에 직면하고 있다. 이는 미국에서 판매된 약 1,600만 대의 차량 중 거의 절반을 수입한 산업을 재편할 가능성이 있다.

트럼프의 관세 위협이 이 산업에 1,000억 달러의 규모의 혼란을 초래

Movers

APTV

TSLA

뱅크오브아메리카는 2025년에 실적이 개선될 것으로 예상되는 주요 자동차 주식 3종목으로 페라리(RACE), 앱티브(NYSE:APTV) 및 오토네이션(NYSE:AN)을 선정했다. 이들 기업은 최근의 변동성과 섹터 내 과제에도 불구하고 자동차 산업의 지속적인 추세로부터 혜택을 받을 수 있는 좋은 위치에 있다고 강조했다.

뱅크오브아메리카: 2025년 상승할 자동차 주식 3종목은?

럭셔리 자동차 판매와 관련하여, 페라리(NYSE:RACE), 롤스로이스 및 마세라티와 같은 브랜드들은 그들의 차량만큼이나 화려한 전략을 사용한다. 이 자동차 제조사들은 고객이 그들의 차량을 거부할 수 없게 만드는 방법을 잘 알고 있으며, 때로는 고객들이 회사를 대신하여 일을 해주고 있다는 느낌을 받게 하여 마치 좋은 거래를 하고 있는 것처럼 느끼게 만든다.

페라리는 고객을 상대로 영리한 방법을 고안, 롤스로이스와 마세라티는 다른 길을 선택

Ferrari NV

Race Oncology Ltd

Needham analyst Bernie McTernan reiterates AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from Hold to Hold.

Reiteration

Analyst Ratings

Needham Reiterates Hold on AppLovinto Hold

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) with a Buy and maintains $5 price target.

Price Target

RLYB

HC Wainwright & Co. Reiterates Buy on Rallybio, Maintains $5 Price Target

Evercore ISI Group analyst Steve Sakwa upgrades SL Green Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) from In-Line to Outperform and lowers the price target from $74 to $73.

Upgrades

Evercore ISI Group Upgrades SL Green Realty to Outperform, Lowers Price Target to $73

GRMN

Garmin Says G3000 PRIME Integrated Flight Deck Selected By Pilatus For Its New PC-12 PRO Aircraft

MDIA

Spectral AI Reports Results Of Performance Of Its DeepView System In Connection With Completion Of Its Burn Validation Study

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) with a Buy and maintains $10 price target.

ZNTL

HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $10 Price Target

PBGENE-HBV is the first-ever investigational in vivo gene editing therapy cleared to enter clinical trials for the treatment of chronic hepatitis B in the United States (U.S.) –
- IND clearance represents a significant regulatory milestone for PBGENE-HBV –
- Company to expand its Phase 1 ELIMINATE-B study to the U.S., joining world-class clinical sites in Moldova, Hong Kong, and New Zealand where strong clinical execution is currently underway –

DTIL

Precision BioSciences Achieves Regulatory Milestone As FDA Clears IND For First-in-Class PBGENE-HBV Gene Editing Therapy For Chronic Hepatitis B

Founder and Chairman of the Board, Michael Heffernan, and Board Member, Gwen A. Melincoff, will retire from Collegium's Board at the Annual General Meeting (AGM) on May 15, 2025, and Gino Santini, the Board's Lead Independent Director, will become Chairman.&nbsp;

Management

COLL

Collegium Names Gino Santini As Chairman; Michael Heffernan And Gwen Melincoff To Retire From Board

HROW

Harrow Unveils VEVYE Access For All Initiative

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia
First-in-class Bruton's tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary name "bexobrutideg" in newly named degrader class of drugs

Biotech

Health Care

General

NRIX

The FDA Has Granted Orphan Drug Designation To Nurix Therapeutics' Bexobrutideg (NX-5948) For The Treatment Of Waldenström Macroglobulinemia

D. Boral Capital analyst Jason Kolbert initiates coverage on Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) with a Buy rating and announces Price Target of $9.

Initiation

PSTV

D. Boral Capital Initiates Coverage On Plus Therapeutics with Buy Rating, Announces Price Target of $9

Patients in this cohort are receiving [212Pb]VMT01 at 1.5 mCi in combination with nivolumab, a PD-1 blocking antibody developed and marketed by Bristol Myers Squibb as Opdivo&#xAE;. Patients in earlier cohorts received [212Pb]VMT01 as monotherapy. Initial results from the earlier cohorts were previously presented at the <a href="https://www.globenewswire.com/Tracker?data=lbnqdoEdOBXDI0tazCF7O6Gm7aX960Z1DPz2hC7XVYWhydPL2gB28iRuKsyv7ZVPFqojoIIM72ZkxXaHKLxmJt6PtL3nFc73iqhtgo0Yz-LnEZm3oXkwl2rnwMjMCskTVi4Poh6LA4DWRL6fyrFyOWegGsn_SutWUndN7X518RZuVXN46SyFeCQbKYM-LL2KR7mx-p2m7KH6VzfFKZWpEg==">21st International Congress of the Society for Melanoma Research</a> (SMR) in October 2024.

CATX

Perspective, Therapeutics Has Dosed The First Patient In A New Cohort Of A Phase 1/2a Trial Evaluating The Safety Of [212Pb]VMT01, A Targeted Alpha-particle Therapy, In Patients With Histologically Confirmed Melanoma And Positive Melanocortin 1 Receptor Imaging Scan

TVTX

Travere Submits sNDA To FDA For Seeking Priority Review For Traditional Approval Of FILSPARI For Focal Segmental Glomerulosclerosis Treatment

Guidance

SAIC

Science Applications Intl Revised FY26 Revenue Outlook To $7.60B-$7.75B From $7.55B-$7.75B (Vs. Cons. $7.644B), Adj. EPS To $9.10 - $9.30 From $8.90 - $9.10 (vs. Cons. Of $9.07)

<ul>
<li>Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control</li>
<li>Rapid and significant improvements in disease clearance with ZORYVE cream with children and adults reaching validated Investigator Global Assessment – Atopic Dermatitis (vIGA-AD) Success at week 4, with significant improvements seen as early as week 1</li>
<li>Demonstrated efficacy and tolerability in treating facial involvement in AD, which affected 42% of trial participants</li>
<li>Shown to deliver sustained improvement in disease control for up to 56 weeks of treatment</li>
</ul>

ARQT

The Health Canada Has Approved Arcutis' Approved Zoryve (Roflumilast Cream 0.15%), For The Treatment Of Mild To Moderate Atopic Dermatitis In Adults And Children Ages 6 Years And Older

BECN

QXO In Discussions To Acquire Beacon Roofing Supply For $124.35 Per Share In All-Cash Deal Worth ~$11B

D. Boral Capital analyst Jesse Sobelson maintains FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) with a Buy and maintains $3.75 price target.

NOTE

D. Boral Capital Maintains Buy on FiscalNote Holdings, Maintains $3.75 Price Target

Contracts

PRSO

Peraso Receives $3.6M Purchase Order For Its mmWave Devices From A Provider Of Wireless Networking Systems

<ul>
<li>On track for year end 2025 BLA submission for accelerated approval of 5 mg/kg every six weeks of del-zota in DMD44</li>
<li>Consistent favorable safety and tolerability across del-zota dose cohorts&nbsp;</li>
<li>Plan to present functional data in fourth quarter of 2025</li>
</ul>

Avidity Biosciences Announced Del-Zota Topline Data From The Phase 1/2 Explore44 Trial For Duchenne Muscular Dystrophy Amenable To Exon 44 Skipping, Demonstrating Consistent, Statistically Significant Improvements In Dystrophin, Exon Skipping And Creatine Kinase As Well As Favorable Safety And Tolerability

Following the close of the transaction, the Company expects its outstanding share count to be reduced by approximately 12% and the transaction is expected to close on or around March 18, 2025.
Concurrent with the announced stock transaction, the Company also announced that Jonathan Seiffer will step down from the Board of Directors, effective immediately.
 &nbsp;

Buybacks

ASLE

AerSale To Repurchase Approximately 6.428M Shares Of Stock From Its Long-term Private Equity Sponsor Leonard Green & Partners At Negotiated Price Of $7.00 Per Share

Press Releases

FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM

ANOTHER YEAR OF STRONG PERFORMANCE, ALL 2024 TARGETS EXCEEDED. FURTHER GROWTH IN 2025.

DIVIDEND DISTRIBUTION PROPOSAL

FERRARI RELEASES ITS 2024 ANNUAL REPORT AND FILES ANNUAL REPORT ON FORM 20-F

Ferrari: Announcement of the Seventh Tranche of the Multi-Year Share Repurchase Program by Participating as a Purchaser in Exor's Accelerated Bookbuild Offering

Comments

Ferrari

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌